[ad_1]
© Reuters. FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
(Reuters) – AbbVie Inc (NYSE:) said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson’s disease therapy for adults.
The U.S. health regulator has sought additional information about the delivery pump, which is part of the marketing application, the drugmaker said, and does not want additional efficacy and safety trials.
Abbvie said it plans to resubmit the marketing application as soon as possible.
Parkinson’s disease is a neurological disease that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination.
[ad_2]
Source link
(This article is generated through the syndicated feed sources, Financetin doesn’t own any part of this article)
